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Fig 1. Disseminated cutaneous leishmaniasis in patient
with Sezary syndrome. Erythematous papulonodules on
the trunk.
Fig 2. Disseminated cutaneous leishmaniasis in patient
with Sezary syndrome. Large numbers of Leishmania
amastigotes within the macrophages (arrows). (Hematox-
ylin and eosin; original magnification: 3640.)
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Disseminated cutaneous leishmaniasis in a
patient with Sezary syndrome
To the Editor: A 66-year-old Caucasian man was
diagnosed with Sezary syndrome (SS) in 2007.
After chlorambucil, prednisone, and bexarotene
treatment, only a partial response was achieved.
In May 2012, he was hospitalized with necrotizing
pneumonia. He presented with typical features of SS:
erythroderma, pruritus, and enlarged lymph nodes.
Laboratory studies showed total leukocytes
8.2 3 109/L (normal range: 4-11 3 109/L), 84.5%
neutrophils, and 8.2% lymphocytes, of which 35%
were Sezary cells. Increased lactate dehydrogenase,
520 U/L (normal range: 250-450 U/L), was also seen.
The patient had numerous asymptomatic
hyperpigmented macules on his trunk and limbs,
which appeared over the previous 6 months.
Histopathologic examination of lesions showed
acanthosis, epidermotropism, and a mild perivascu-
lar atypical lymphoid infiltrate in the upper dermis.
Lymphocytes were hyperchromatic, with indented
cerebriform nuclei, and expressed CD2, CD3, CD4,
and CD5, with partial loss of CD7.
Five months later, the patient was readmitted
with fever, malaise, and progression of skin lesions.
Cutaneous examination revealed numerous wide-
spread erythematous papules and nodules (Fig 1). AOpen access under CC BY-NC-ND license.skin biopsy showed a dense lymphohistiocytic
infiltrate in the upper and middle dermis with intra-
cellular microorganisms suggestive of Leishmania
amastigotes (Fig 2). Disseminated cutaneous leish-
maniasis was diagnosed and confirmed by positive
polymerase chain reaction for Leishmania infantum.
Bone marrow aspirate was negative for Leishmania.
Liposomal amphotericin B (4 mg/kg/day intrave-
nously) was given for 10 days without clinical
improvement, so treatment was switched to meglu-
mine antimonate (20 mg/kg/day intravenously).
After the first dose, the patient’s condition worsened;
fever and flare of cutaneous lesions developed.
Jarisch-Herxheimer reaction was diagnosed and the
Fig 1. Toxic epidermal necrolysis. A, Clinical presentation
on day 30 after initial chemotherapy. Skin lesions on the
back showed exudative erythema with positive Nikolsky
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Myalgias, impaired renal function, and leucopenia
developed. Even though treatment was discontinued
13 days later, skin lesions progressively improved.
Twomonths later the patient died due to progression
of the lymphoproliferative process.
SS is a primary cutaneous T-cell lymphoma
associated with dysregulation of both cellular and
humoral immunity.1 Staphylococcus aureus has been
identified as the most common pathogenic organism
in cutaneous infections and bacteremias in patients
with SS. Disseminated herpes infections are also
frequently found with progressive cell-mediated
immunity decline.1 Leishmaniasis due to L. infantum
is endemic in Spain, both in immunocompetent and
in immunosuppressed patients, and is transmitted by
mosquitoes.2Disseminated cutaneous leishmaniasis is
rarely seen in SS. To our knowledge, there is only
one report of cutaneous leishmaniasis in a patient
with SS.3
Cutaneous leishmaniasis caused by dermotropic
species may disseminate in immunosuppressed
patients and present different clinical characteristics.
Poor response to treatment is common and relapses
are frequent,4 depending on the Leishmania strain.5
Differential diagnosis of disseminated cutaneous
eruptions in immunocompromised patients must
include other infectious diseases such as leish-
maniasis, histoplasmosis, sporotrichosis, and para-
coccidioidomycosis. Histopathologic examination is
necessary for the diagnosis of cutaneous leishman-
iasis, although the parasites may not be found. If
clinical suspicion is high, polymerase chain reaction
may be useful.5
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circulating T cells: A possible role for resident
memory T cells
To the Editor: Toxic epidermal necrolysis (TEN) is a
life-threatening mucocutaneous disease with high
mortality, mainly induced by drugs. Although the
pathogenesis of TEN remains elusive, reports have
suggested the importance of T lymphocytes.1,2 Here,
we report a case of TEN that occurred in the absence
of circulating leukocytes but in the presence of
resident memory T cells (TRM), suggesting key role(s)
for TRM in the pathogenesis of TEN.
